Joyant Pharmaceuticals joyantpharma.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Joyant Pharmaceuticals is focused on the development of small molecule therapeutics for cancer and inflammation. Joyant is developing several programs based upon their understanding of the molecular events that control growth, replication and apoptosis.

Joyant Pharmaceuticals is focused on the development of small molecule therapeutics for cancer and inflammation. Joyant is developing several programs based upon their understanding of the molecular events that control growth, replication and apopto...Show all

Company (Alive / Active)

Phone:

Fax:

2620 N. Stemmons Freeway
Dallas, 75207
Texas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Joyant Pharmaceuticals $0M Nov 30, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Joyant Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

GlycoMimetics

Gaithersburg, Maryland, United States
IPO / Went publicGlycoMimetics is developing small molecule drugs that mimic the actions of carbohydrates using glycobiology. The company is focusing its initial efforts on therapeutics to treat inflammatory diseases such as cystic fibrosis and cancer.Login to see details

Tragara Pharmaceuticals

San Diego, California, United States
Alive / ActiveTragara Pharmaceuticals is a pharmaceutical company focused on the clinical and commercial development of drugs for the treatment of various cancers. TG02 is an orally available, small molecule that targets - equipotently - the major signaling pathways involving ERK5, JAK2, and key cell cycle and transcriptional cyclin-dependent kinases (CDKs), with pharmacological and pharmaceutical properties. Preclinical models demonstrate that TG02 has the ability to deplete the short-lived survival proteins...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Diazonamide analogs Nov 25, 2013 Sep 30, 2014 Patent
Smac mimetic dimers and trimers useful as anti-cancer agents Apr 11, 2008 Feb 04, 2014 Patent
Diazonamide analogs Apr 15, 2012 Nov 26, 2013 Patent
Small molecule apoptosis promoters Jun 28, 2012 Nov 19, 2013 Patent
Dimeric smac mimetics Oct 28, 2010 Oct 08, 2013 Patent
See all 17 patents